a secretin-like protein that probably oligomerizes, with the help of the lipoprotein PscW, to form a channel through the bacterial outer membrane 13, 14 . based on studies of its Yersinia spp. homologue, PscP is likely to be a molecular ruler that dictates the needle length 15 . PscJ is predicted to be a lipoprotein component of the basal substructure of the needle complex 16 . Although some progress has been made, considerable additional effort will be required to fully understand the complex mechanism by which the needle complex functions in the secretion process.
The translocation apparatus
The translocation apparatus is a proteinaceous membrane pore that accepts the effector proteins that are secreted by the needle complex and delivers them across the Figure 1 | An overview of Pseudomonas aeruginosa type III secretion. a | Thirty-six genes encoded in five clustered operons, together with at least six other genes scattered around the chromosome, are involved in the type III secretion system. b | The type III secretion system (T3SS) can be functionally divided into five components: the needle complex, the translocation apparatus, the regulatory proteins, the effector proteins and the chaperones. These five parts work together to inject effector proteins into host cells in a highly regulated manner. c | The linkage of T3SS transcription to protein secretion is achieved through the interactions of four proteins: ExsA, ExsC, ExsD and ExsE. When secretion is turned off, ExsE accumulates in the bacterium and binds ExsC, allowing ExsD to bind ExsA and thus preventing the transcription of the type III secretion genes. When secretion is activated, the regulatory protein ExsE is secreted from the cell, allowing ExsC to bind ExsD. This sequestration of ExsD frees the transcriptional activator ExsA and results in the unimpeded transcription of type III secretion genes. cAMP, cyclic AMP; exo, exoenzyme; RNAP, RNA polymerase; S, ExoS; T, ExoT; U, ExoU; Y, ExoY.
Inflammasome
A multiprotein cytoplasmic complex that mediates the activation of caspase 1 in order to promote the maturation of the interleukins IL-1β and IL- 18 . This activation may also lead to a form of cell death termed 'pryoptosis' . The inflammasome itself may be activated by NOD-like receptors in response to intracellular microbial triggers.
Flagellin
The protein monomer that forms the hollow filament of the bacterial flagellum.
AraC/XylS family
A large family of transcriptional activators that are defined by a 100-amino acid region of sequence similarity. These proteins regulate diverse bacterial functions, including catabolism, stress responses and virulence.
host cell plasma membrane (FIG. 1b) . The translocation process is efficient, with less than 0.1% of secreted effector proteins escaping to the extracellular milieu 17 . Like the T3SSs of Yersinia, Salmonella and Shigella spp., the T3SS of P. aeruginosa uses three proteins for translocation: Popb, PopD and PcrV [18] [19] [20] . Popb and PopD are themselves secreted by the type III needle complex and interact with each other and with the host cell membrane in a poorly understood manner to form the translocation pore, which is 2.8-6.0 nm in diameter [18] [19] [20] [21] [22] . Recombinant Popb and PopD were sufficient for the formation of oligomers and ring-like structures in lipid vesicles in vitro 21 , although PcrV was required for pore formation when these two proteins were injected through the needle complex into the plasma membranes of fibroblasts and red blood cells 23 . PcrV is also secreted by the T3SS and is necessary for translocation but does not seem to be part of the pore 23, 24 . It may instead form a multimeric scaffold at the tip of the type III secretion needle, as it has been shown to do when it is artificially expressed as part of the related Y. enterocolitica T3SS 25 . This scaffold may then facilitate the assembly of the PopbPopD translocation pore in the host cell plasma membrane. Alternatively, PcrV may link the needle complex to preformed Popb-PopD pores, forming part of a continuous conduit through which effector proteins move from the bacterial cytosol to the host cell cytosol 26 . The role of the translocation apparatus may not be limited to the transport of effector proteins: the translocation pore itself is sufficient to cause the death of host cells 20, 23, 27, 28 . Death can be caused either directly, through pore-mediated increases in membrane permeability 20, 23, 27, 29 , or indirectly, through the activation of broad cellular defence responses, as has been observed with the T3SSs of other bacterial pathogens 30 . The death of the intoxicated cell in this context may be a protective mechanism of the host rather than a virulence mechanism of the bacterium. Details of such pathways are now beginning to emerge. For example, in the absence of any of the known effector proteins, a P. aeruginosa type III secretion and translocation apparatus is sufficient to trigger the inflammasome-mediated activation of caspase 1 through ice protease activating factor (IPAF; also known as NLRD4), a Nod-like receptor family member and cytosolic sensor of bacterial products [31] [32] [33] [34] . As has been shown with S. enterica type III and Legionella spp. type IV secretion, the formation of the translocation pore may facilitate the entry of flagellin into the cytosol, where it is recognized by IPAF, although this possibility remains controversial in P. aeruginosa type III secretion [31] [32] [33] [34] . Activation of the inflammasome and caspase 1 results in the production of the interleukins IL-1β and IL-18 and in pyroptosis 20, 32, 33 , which is a form of cell death that is pro-inflammatory and that has features of both apoptosis and necrosis 35 . The induction of pyroptosis may explain previous reports of the T3SS-dependent but effector-independent death of phagocytes 20, 23, 27, 28 . As bacterial burdens were higher after 12 hours of intraperitoneal infection in Ipaf -/-mice than in controls, inflammasome activation seems to be protective and may be an important aspect of the innate immune response against P. aeruginosa
.
Regulation of type III secretion Type III secretion in P. aeruginosa is regulated at two levels: transcription of T3SS genes and initiation of secretion itself. These levels are linked, as transcription is induced upon activation of the secretion process 4, 36 , and this coupling allows type III secretion components to be produced at high levels when they are most needed -following contact with host cells.
At its most proximal level, the transcription of T3SS genes is controlled by exsA, a member of the AraC/XylS family of transcriptional regulators. exsA binds to the promoters of T3SS genes, including its own promoter, in a region of DNA that extends through the putative -35 RNA polymerase binding site and the 18 nucleotides upstream 37, 38 . This region includes an adenine-rich sequence at -55 nucleotides that is sometimes referred to as an exsA consensus element 37, 38 . An elaborate 'catch and release' mechanism involving three additional proteins, exsC, exsD and exse, links exsA-mediated transcriptional activation to secretion (FIG. 1c) . under conditions that prevent secretion, exsA is bound by the 'anti-activator' exsD, which inhibits exsA-dependent transcription 36 . exsC, an 'anti-anti-activator' , has the potential to disrupt the exsD-exsA interaction by directly binding to and sequestering exsD 39 but is prevented from doing so under non-secreting conditions by its higher binding affinity for exse 40, 41 . The coupling of transcription with secretion is achieved by the export of exse through the type III needle complex into either the medium or the host cell cytosol during secretion 42 . Therefore, under conditions that promote secretion, exse levels in the bacterium are depleted and the paucity of exse frees exsC to bind exsD, allowing unimpeded Box 1 | Evolution of the Pseudomonas aeruginosa type III secretion system Type III secretion systems (T3SSs) share a common ancestor with flagellar systems 163 , but the phylogenies of the flagellar systems follow those of their source organisms whereas the clusters of genes encoding the T3SSs do not, indicating that there has been interspecies horizontal gene transfer for these systems 164 . The Pseudomonas aeruginosa T3SS belongs to the Ysc family of type III systems, which includes the Yop system of Yersinia spp., the Asc system of Aeromonas salmonicida, the Lsc system of Photorhabdus luminescens, the Vcr system of Vibrio parahaemolyticus, the Bsc system of Bordetella spp. and the Dsc system of Desulfovibrio vulgaris 165 . The selective pressures driving the evolution of the P. aeruginosa T3SS are unclear. P. aeruginosa is an opportunistic pathogen in humans, meaning that it usually infects only individuals who are immunocompromised in some way 1 . Most infections are therefore 'iatrogenic' -the consequence of procedures and treatments of modern health care. Even individuals with cystic fibrosis rarely lived long enough to acquire a P. aeruginosa infection before the advent of modern antimicrobial therapies 166 . For this reason, it is unlikely that the P. aeruginosa T3SS evolved as a result of the pressures to survive within humans. What then is the natural target of the P. aeruginosa T3SS? P. aeruginosa is an environmental bacterium that must avoid or survive predation by the many organisms that inhabit the soil and natural bodies of water, and its T3SS may have evolved for this purpose. In support of this notion, most environmental P. aeruginosa isolates have functional T3SSs 167 , and the T3SS effectors ExoU, ExoS, ExoT and ExoY each facilitate the killing of environmental amoebae during co-cultivation 168, 169 . Therefore, this system may have initially evolved to ward off environmental predators, and the broad conservation of targeted substrates across eukaryotic organisms may have resulted in a system that is also active against human cells.
Adenylyl cyclase
An enzyme that catalyses the conversion of ATP to cAMP and pyrophosphate.
cAMP receptor protein
A regulatory protein that, in the presence of cAMP, binds tightly to a specific DNA sequence in the promoters of a subset of bacterial genes, modulating their transcription. Also known as catabolite gene activator protein (CAP).
Two-component signal transduction system
A system that is commonly used by bacteria to couple environmental stimuli to response mechanisms. They consist of sensor and response regulator components that are linked by phosphorelays.
transcriptional activation of type III secretion genes by exsA. The net result of this regulatory cascade is that the production of T3SS proteins, including needle complexes and effector proteins, is maintained at low basal levels until contact with host cells activates secretion, when their expression is rapidly increased.
Two global regulatory systems, both of which respond to poorly defined environmental stimuli, are known to work through exsA to regulate transcription of T3SS genes: the intracellular cyclic AmP system and the Gac regulatory system. In the cAmP pathway, the inner-membrane adenylyl cyclase protein Cyab responds to inducing signals by increasing the intracellular cAmP levels 43 . cAmP is thought to allosterically regulate Vfr, a global regulatory protein with homology to the Escherichia coli cAMP receptor protein (Crp) 43 . cAmP and Vfr, together with exsA, regulate expression from T3SS promoters in a poorly understood manner. In the Gac system, the two-component signal transduction system sensors RetS and LadS transduce environmental signals to modulate the two-component GacA-GacS system, which in turn regulates the expression of T3SS genes. RetS primes P. aeruginosa for acute infections by inducing T3SS genes and normal piliation but repressing genes that promote biofilm growth, whereas LadS acts in a reciprocal manner by downregulating type III secretion during chronic infections [44] [45] [46] [47] 
.
For a more detailed, recent review of the transcriptional regulation of the P. aeruginosa T3SS, see REF. 48 .
The triggering of secretion is complex and not well understood. It is known that the physiological stimulus is contact with host cells, whereas the most commonly used laboratory signal is exposure to Ca 2+ -depleted medium 49, 50 . Low Ca 2+ concentrations alone are insufficient to trigger secretion and must be accompanied by the presence of certain amino acids, such as glutamate 51 . This is probably due to there being a role for the citric acid cycle in type III secretion. mutations in the genes encoding citrate synthetases, pyruvate dehydrogenase and GltR (the regulator of the glucose transporter) all prevented the induction of type III secretion 43, 51, 52 . In fact, metabolic stress in general modulated the ability of P. aeruginosa to secrete type III proteins 53 . metabolically unfavourable conditions may reduce overall secretion by decreasing the percentage of bacterial cells that can assemble functional secretion machines on their surfaces 51 .
Chaperones
Some but not all T3SS-secreted proteins have cognate chaperones to which they bind before secretion. These chaperones can facilitate both the storage of their cognate protein partners in the bacterial cytosol and the appropriate delivery of these partners to the secretion apparatus 54 . SpcS (previously known as orf1) serves as a chaperone for both exoS and exoT (see below for a discussion of the effectors) and is required for maximal secretion of these proteins 55, 56 (FIG. 1b; TABLE 1 ). Spcu is a chaperone for exou 57 , and no chaperone has yet been identified for exoY. Chaperones also exist for T3SS-secreted proteins that are not effectors of the secretion system; for example, PcrH is a chaperone for the translocation proteins Popb and PopD 21 , Psce and PscG are chaperones for PscF, which is the structural subunit of the needle complex 58 , and exsC is a chaperone for the regulatory protein exse 40, 41 .
The effectors
Despite extensive characterization by several laboratories, only four effector proteins of the P. aeruginosa T3SS have been identified: exoS, exoT, exou and exoY (TABLE 1) . The P. aeruginosa T3SS seems to have fewer effector proteins than any other well-characterized T3SS. For example, the Yersinia spp. Yop T3SS has 6 known effector proteins, the S. enterica SPI1 system has at least 13, the S. enterica SPI2 system has at least 10 and the Shigella spp. system has approximately 25. The relative dearth of effector proteins in P. aeruginosa is especially surprising given the wide range of hosts and environments with which the bacterium is associated, but it may reflect the large number of other secretion systems that are encoded by this species. Alternatively, the small number of effector proteins may have been evolutionarily balanced by their activity against an extremely broad range of eukaryotic organisms.
Although almost all P. aeruginosa strains harbour the genes that encode the type III secretion machinery, most strains do not carry a complete set of the genes that encode the effectors 59, 60 . In isolates from acute infections, the exoS gene is found in 58-72% of isolates, the exoU gene in 28-42%, the exoY gene in 89% and the exoT gene in 92-100%. For reasons that are not clear, nearly all strains have either the exoS or the exoU gene but not
Box 2 | Pseudomonas aeruginosa type III secretion in chronic infections
Pseudomonas aeruginosa type III secretion plays a dominant part in acute infections, but emerging evidence suggests that it may actually be selected against in chronic infections, such as those afflicting individuals with cystic fibrosis (CF). Many patients with CF and chronic P. aeruginosa infection have antibodies against type III effector proteins 170 , suggesting that these factors are expressed at some point during the infection. However, P. aeruginosa strains gradually lose their ability to secrete type III proteins in the airways of these patients 27, 151, 171 . This phenomenon may occur through a number of different mechanisms. P. aeruginosa isolates from chronically infected patients with CF often have a mucoid phenotype that results from the overexpression of the exopolysaccharide alginate. In these strains, alginate is often overproduced because of mutations in the mucA gene 172 ; these mutations also result in repression of type III secretion genes 173 . A second mechanism is the RetS-LadS-GacA-GacS regulatory system (described in the main text), which allows P. aeruginosa to switch from an acute to a chronic infection mode. Finally, over a period of years in the airways of patients with CF, mutations accumulate in genes that are essential for type III secretion, such as cyaB, vfr and exsA 174 . Therefore, multiple mechanisms cause the attenuation of type III secretion during infections of patients with CF, underscoring the strength of the selection against this system. It may be that the secretion of destructive toxins is not compatible with bacterial persistence in the airways for years or that T3SS proteins are attractive targets for the host immune system.
GTPase-activating protein
A member of a family of regulatory proteins that stimulate the intrinsic GTPase activity of small signalling G proteins, which results in their inactivation.
ADP ribosyl transferase activity
The enzymatic activity that covalently transfers an ADP-ribose group from NAD + to a substrate protein, usually altering the activity of the substrate.
both. As described below, the secreted effector proteins define the phenotype of a strain during infection 60, 61 . For example, exoS-secreting strains cause delayed cell death with features of apoptosis, whereas exou secretion is associated with rapid and robust host cell lysis.
ExoS. exoS is a bifunctional toxin that has both GTPaseactivating protein (GAP) activity and ADP ribosyl transferase (ADPRT) activity (TABLE 1) . This effector protein has a modular domain structure that underscores the complexity of its interactions with host cells (FIG. 2) .
As with other type III effector proteins, the extreme amino terminus of exoS carries the information for its targeting to the type III secretion apparatus. Although no consensus sequence has been identified, the first 15 amino acids of exoS presumably encode the information that is necessary for secretion through this apparatus 4 . Residues 15-51 are thought to constitute a binding site for the exoS chaperone, SpcS 62 . Residues 51-72 contain a symmetrical leucine-rich motif that forms the membrane localization domain (mLD) 63 , which is responsible for the initial transient localization of exoS to the plasma membrane of the host cell 64 (FIG. 3) . Subsequent trafficking to the Golgi and endoplasmic reticulum in the perinuclear region of the cell occurs in association with markers for RAb5-containing early endosomes and RAb6-and RAb9-containing late endosomes 64, 65 . of note, the localization of exoS to these membrane compartments is essential for the efficient modification of its substrates 66, 67 . Residues 96-233 of exoS form a GAP domain that targets Rho, Rac and cell division cycle 42 (CDC42) 68, 69 , which are small GTPases that maintain the organization of the host cell actin cytoskeleton. These regulatory GTPases normally switch between an active, GTP-bound form and an inactive, GDP-bound form, but the exoS GAP domain biases this switch towards the GDP-bound, inactive form, leading to the disruption of the host cell actin cytoskeleton 68, 69 . The GAP domain has functional and structural similarity to other type III effector proteins, such as Yope of Yersinia spp. and StpP of S. enterica 70, 71 . The three-dimensional structure of the exoS GAP domain bound to RAC1 indicates that exoS uses an arginine finger (Arg146) to stabilize the RAC1 transition state and maintain its intrinsic GTPase activity 72 . This in turn results in GTP hydrolysis to GDP, causing the GDP-bound form of RAC1 to predominate 69, 73 and leading to inactivation of Rac signalling 74 . The transient disruption of the actin cytoskeleton by the GAP activity of exoS is associated with cell rounding and decreased internalization of P. aeruginosa by certain cell types, suggesting that it has a role in preventing phagocytosis [75] [76] [77] . The ADPRT domain of exoS resides between residues 233 and 453 (REF. 78 ). Residues 418 to 429 contain a binding site for a eukaryotic cofactor that is necessary for the activation of ADPRT activity but not for GAP activity 79, 80 . This cofactor was initially designated factor activating exoS (FAS) but was later shown to be a 14-3-3 protein 81, 82 . These proteins serve as regulatory factors that modulate a wide range of cellular functions, including cell cycle progression, protein trafficking and apoptosis. Similarly to other 14-3-3 ligands, exoS binds in a conserved amphipathic groove but does so in the opposite orientation to most ligands and uses unique intermolecular interactions 83 . Deletion of the 14-3-3 binding site renders exoS unable to interact with its cofactor and results in the loss of its ADPRT activity and the consequences that this activity has for mammalian cells (see below) 83 . The requirement for a host cell cofactor prevents this potent weapon from being turned against P. aeruginosa itself, by precluding exoS activation until after it is injected into the host cell.
Following its injection and activation, the ADPRT activity of exoS has several adverse effects on the host cell, including cell death, actin cytoskeleton disruption (associated with cell rounding) and inhibition of DNA synthesis, vesicular trafficking and endocytosis 74, [84] [85] [86] . The irreversible disruption of the cytoskeletal structure may contribute to a reduction in cell-cell adherence, which in turn may facilitate P. aeruginosa penetration through epithelial barriers 74, 84, 86 . The cell death that is induced has features of apoptosis, although loss of cell membrane integrity, which is more characteristic of necrosis, is also observed 84, 87 . It has been postulated that the exoS-mediated killing of host immune cells may allow P. aeruginosa to persist in the presence of a vigorous host immune response, although it is not clear which cell types are targeted by exoS in vivo. Alternatively, this form of cell death may be similar to pyroptosis, possibly being the culmination of a host cell response to the presence of exoS, with the aim of eliminating intoxicated cells. much effort has been made to define the substrates that are modified by exoS and that lead to these pathogenic changes; however, this has been complicated by the promiscuous nature of the ADPRT activity of this toxin. exoS catalyses the transfer of ADP-ribose to many different host proteins 85, [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] (TABLE 1) , and the challenge has been to link ADP ribosylation of specific substrates to the observed host cell phenotypes. Two substrates of special interest are RAS, a small GTPase, and the ezrin, radixin and moesin (eRm) family of proteins. As RAS signalling affects cellular proliferation, survival and cytoskeletal structure, RAS has been an attractive candidate for the pathogenically relevant target of exoS. modification of Arg41 of RAS results in the inhibition of the GDPto-GTP exchange that is normally catalysed by the guanine nucleotide exchange factor of the protein 98 . This in turn disrupts signalling by preventing the association of RAS with its downstream effector, RAF1 (REFS 99-101). overexpression of constitutively active RAS or protein kinase b (also known as AKT1), a downstream component of the RAS signalling pathway, prevented exoSmediated cell killing, indicating that exoS modification of RAS is biologically important 102 . exoS lacking the mLD was found to localize within the cytosol and failed to appropriately ADP ribosylate membrane-associated RAS, demonstrating the importance of exoS localization in the cell 103 (FIG. 3) . The eRm family of proteins 96 bind actin and play an important part in many actin processes, including motility, phagocytosis, adhesion and the maintenance of cell shape. ADP ribosylation of eRm proteins prevents their phosphorylation and results in their inactivation 104 . In support of the biological relevance of this modification, a dominant active moesin prevented the cell rounding that is normally associated with exoS intoxication 104 . Therefore, the ADPRT activity of exoS seems to target a number of distinct cell factors and pathways to compromise the host cell.
ExoT. exoT shares 76% amino acid identity with exoS and is also a bifunctional toxin with N-terminal GAP activity and carboxy-terminal ADPRT activity (TABLE 1) . Although not as thoroughly studied, the domain structure of exoT seems to be similar to that of exoS in that residues 1-50 probably encode secretion and chaperone binding information and residues 51-72 are thought to encode an mLD 62 (FIG. 2) .
Similarly to exoS, exoT residues 78-235 contain GAP activity towards Rac, Rho and CDC42 (REFS 105, 106) . This activity seems to be similar to that of the N terminus of exoS and causes reversible disruption of the actin cytoskeleton that manifests as cell rounding, cell detachment and inhibition of cell migration and phagocytosis 76, 77, 106 . The GAP activity of exoT also contributes to the inhibition of cytokinesis through the inactivation of RHo 107, 108 . In another similarity to exoS, residues 235-457 of exoT encode an ADPRT domain that requires binding of the host cell cofactor 14-3-3 for activation 109 . However, in contrast to exoS, exoT ADP ribosylates a distinct and limited number of host proteins (TABLE 1) . In particular, exoT modifies the CT10 regulator of kinase (CRK) I and CRKII adaptor proteins 110 . Hybrid protein experiments and structural modelling indicated that one small α-helical region ('region A') that is present in exoT but absent in exoS conferred specificity for the CRK proteins 111 . exoT ADP ribosylates CRKI at Arg20 and ExoS is a 453-amino acid bifunctional toxin that has both GTPase activating protein (GAP) and ADP ribosyl transferase (ADPRT) activity. Arg146 is required for the GAP activity and both Glu379 and Glu381 are required for efficient catalytic addition of the ADP-ribose moiety of NAD + to the substrate 175 . Within the ADPRT domain, residues 418 to 429 (labelled as CF) comprise a binding site for the eukaryotic cofactor 14-3-3, which is necessary for activation of the ADPRT activity of ExoS. ExoT is a 457-amino acid protein that is closely related to ExoS. Arg149 is required for the GAP activity of ExoT 76 and residues Glu383 and Glu385 are crucial for its ADPRT activity 175 . Residues 422-433 (CF) are thought to constitute the site of 14-3-3 binding. ExoU is a 687-amino acid protein that contains a patatin-like domain that is necessary for phospholipase A 2 activity. Residues Ser142 and Asp344 are required for this activity 117, 118, 121 . ExoY is a 378-amino acid adenylyl cyclase. Residues Lys81, Lys88, Asp212 and Asp214 are required for its activity and are thought to be necessary for interactions between ExoY and ATP. CBD, chaperone binding domain; CF, cofactor binding site; MLD, membrane localization domain; S, secretion signal. this interferes with CRK signalling by preventing the association of CRKI with the focal adhesion proteins p130 cas and paxillin. This has multiple effects on host cells, including the disruption of signalling to RAC1 and the blockage of cell division at the cytokinesis stage 107, 108 . The GAP and ADPRT activities of exoT therefore work together to alter the host actin cytoskeleton and to inhibit cell migration, adhesion and proliferation. The net effect of these activities is to block phagocytosis and disrupt epithelial barriers in order to facilitate bacterial dissemination 27, 28, 76, 112 . In addition, the enzymatic activities of exoT have been linked to delays in wound healing 113, 114 , which may augment the opportunistic capacity of P. aeruginosa by allowing it to more fully exploit breaches in mucosal barriers. Although exoT was initially reported to have no effect on cell viability, it does cause apoptosis-like cell death, predominantly through its ADPRT activity, at later time points (10 hours, compared with 2-5 hours) than for exoS-mediated killing 29 . Apoptosis may be a consequence of the inhibition of CRK signalling, which has been linked to this form of cell death 115 . multiple studies have shown a pathogenic role for exoT, but its contribution to disease in mammalian models has been modest relative to that of exou and exoS 27, 28, 76, 112 . exoT forms a complex with CRK proteins and a CRK ligand, the E3 ubiquitin ligase CbL-b 116 , leading to the polyubiquitylation of exoT by CbL-b and its subsequent proteasomal degradation. Interestingly, CbL-b-deficient mice were more susceptible to infection with an exoT + P. aeruginosa strain than with an exoT -strain, although wild-type mice differed only slightly in this regard 116 . Therefore, CbL-b functions as a host defence molecule by facilitating the degradation of exoT.
ExoU. exou is a potent phospholipase that is capable of causing rapid cell death in eukaryotic cells (TABLE 1) .
Although not yet shown experimentally, the secretion signal that directs exou to the type III secretion apparatus is assumed to be within the first 15 residues of the protein, on the basis of findings from other effector proteins (FIG. 2) . A binding domain for the chaperone of exou, Spcu, lies within residues 3 to 123 (REF. 57 ).
Immediately adjacent to the chaperone-binding site, between residues 107 and 357, is a patatin-like domain that confers phospholipase A 2 (PLA 2 ) activity on the protein 117, 118 . Patatin-like domains are found in several other well-characterized PLA 2 enzymes, such as human Ca 2+ -independent PLA 2 (iPLA 2 ) and human cytosolic PLA 2 (cPLA 2 ) 119 . PLA 2 enzymes hydrolyse the ester bond of the acyl group at the S N 2 position of phospholipids, resulting in the release of free fatty acids and lysophospholipids. The lipase activity of exou has a broad range of substrates, including phospholipids, lysophospholipids and neutral lipids 117, 118, 120 . mutational analysis and sequence alignment with well-characterized PLA 2 enzymes suggest that exou has a serine-aspartate catalytic dyad involving Ser142 and Asp344 (REFS 117, 118, 121) . Subsequent to the identification of the patatin-like domain in exou, similar domains have been identified in a large number of bacterial proteins 122 . Like other P. aeruginosa type III effector proteins, exou requires a eukaryotic cofactor for activation 117, 118 . Fractionation of eukaryotic cell extracts yielded Cu 2+ , Zn 2+ -superoxide dismutase (SoD1) as one such factor 123 . Interestingly, SoD1 enzymatic activity was not necessary for this effect, suggesting that SoD1 activates exou by other mechanisms, such as inducing a conformational change or linking exou to other factors or to its phospholipid substrate. The domain of exou that binds SoD1 has not yet been defined.
The C-terminal half of exou contains no recognizable homology or motifs but is essential for host cell killing 117, 121, 124, 125 . A portion of this part of exou, residues 550-687, is now known to contain an mLD that targets exou to the plasma membrane of the host cell 124, 126 (FIG. 3) .
The remaining portion of the C-terminal half of exou (residues 358-549) may also have an important role in the mode of action of this toxin, as 5-amino acid insertions into this region also destroyed the cytotoxicity of the protein 121 . Another interesting aspect of exou is that it is ubiquitylated: once inside the host cell, two ubiquitin molecules are added to its Lys178. Although ubiquitylation had a modest effect on the exou turnover in cells, it did not appreciably alter the toxicity or localization of the protein 124 . The importance of this modification to the pathogenicity of exou therefore remains unclear.
The net result of intoxication with exou is the death of the host cell. In contrast to the cell killing caused by exoS and exoT, death caused by exou is characterized by a rapid loss of plasma membrane integrity (within 1 to 2 hours), which is consistent with necrosis 127, 128 . exou killing may be directed against phagocytes as well as epithelial barriers, thereby promoting bacterial persistence and dissemination 27, 112, [129] [130] [131] .
ExoY. exoY is a secreted adenylyl cyclase 132 (TABLE 1) .
Two domains of exoY are similar to the corresponding domains of the extracellular adenylyl cyclases of Bordetella pertussis (CyaA) and Bacillus anthracis (edema factor) 132 and act together to bind ATP (FIG. 2) . exoY also requires a host cell cofactor for full enzymatic activity, although the identity of this factor is not known 132 . Injection of exoY into mammalian cells results in an elevation of intracellular cAmP concentration and the differential expression of multiple genes, including many that are known to be regulated by cAmP 132, 133 . These effects lead to the disruption of the actin cytoskeleton 132, 134 , inhibition of bacterial uptake by host cells 135 and increased endothelial permeability 136 . Such activities would be predicted to lead to more severe disease but this has not been uniformly observed 27, 28 , and the significance of exoY in infection remains unclear.
P. aeruginosa type III secretion and disease
Although it is not required for infection 61, 137 , the P. aeruginosa T3SS enhances disease severity in a number of animal models, including acute pneumonia 27, 127, 128, 138 , keratitis 139 , bacteraemia 28 , peritonitis 116 , burn infections 140 and gut-derived sepsis in the setting of neutropenia 141 . The exact role of type III secretion in the pathogenesis of these infections is not clear, but a model is beginning to emerge. This discussion focuses on acute pneumonia, because the largest amount of data is available for this model system (FIG. 4) . Following inoculation into the airways, the first lines of defence faced by P. aeruginosa are the bronchial and bronchiolar epithelia. Intact, polarized epithelia are moderately resistant to P. aeruginosa adherence and invasion, which might explain the opportunistic nature of this bacterium. by contrast, wounded or disrupted epithelia are more susceptible to P. aeruginosa binding and injection of type III proteins [142] [143] [144] . Thus, P. aeruginosa may exploit naturally occurring breaches in epithelial barriers or breaches caused by trauma from endotracheal tubes to gain a foothold in the lungs. The antagonistic effects of exoT towards wound healing might facilitate the ability of the bacterium to take advantage of these vulnerabilities. on contact with sentinel alveolar macrophages, exoS and exou delay or skew the early phases of the inflammatory response by blocking the inflammasome-mediated production of IL-1β and IL-18 (REFS 32, 33) . However, a brisk inflammatory response is eventually induced 130, 131 . exou, which is homologous to cPLA 2 , stokes the inflammatory furnace by generating large amounts of arachidonic acid that in turn leads to increased production of proinflammatory eicosanoids 145 . The ensuing recruitment of excessive numbers of neutrophils and macrophages to the lungs causes collateral damage to host tissues 145 but fails to eradicate the bacteria, perhaps because these phagocytic cells are killed or otherwise impaired by exoS, exoT, exou and exoY on contact with P. aeruginosa 19, 27, 28, 130, 146 . The neutralization of phagocytes also causes localized immunosuppression that predisposes the area to superinfection by other pathogens, as has been observed experimentally and clinically 130, 147 . Failure to eradicate P. aeruginosa from the lungs allows the secreted type III effector proteins and other toxins to injure the pulmonary tissues, which results in the signs and symptoms of pneumonia. Lung compliance is adversely affected by a decrease in the synthesis of the pulmonary surfactant, phosphatidylcholine, and an influx of protein-rich fluid into the alveoli following the disruption of epithelial and endothelial barriers in the lungs by exoS, exoT, exou and exoY 146, [148] [149] [150] . The loss of integrity of these barriers also allows bacterial dissemination into the bloodstream 27,112,128,131 and In early infection, Pseudomonas aeruginosa exploits breaches in the epithelial mucosa, facilitated by ExoT-mediated inhibition of wound healing. ExoU and ExoS block interleukin-1β (IL-1β) and IL-18 production by alveolar macrophages, blunting or biasing the early inflammatory response. When the subsequent development of an inflammatory response does occur, it is excessively amplified by ExoU-induced eicosanoid release and causes collateral damage to host tissues. Furthermore, the recruited phagocytes cannot eradicate P. aeruginosa because they are killed or impaired by ExoS, ExoT, ExoU and ExoY; the resulting paucity of functional phagocytes makes the lungs prone to superinfection by other bacteria. ExoS, ExoT, ExoU and ExoY also disrupt epithelial and endothelial barriers, which allows bacteria and pro-inflammatory cytokines to escape to the bloodstream, leading to bacteraemia and septic shock, respectively. These same breaches allow protein-rich fluid to flow into the air spaces of the lung, which, together with ExoU-mediated decreases in pulmonary surfactant, causes decreased lung compliance and oxygenation.
the leakage of pro-inflammatory cytokines, such as tumour necrosis factor, from the lungs into the systemic circulation; this leads to reductions in mean arterial pressure, cardiac output and base excess, all of which are indicators of septic shock 131 . The net result is the increased mortality that is associated with infection by T3SS + strains 27, 61, 112, 146, 151 .
Human studies and therapeutic interventions
In addition to the abundance of evidence from animal models that supports a role for type III secretion in disease, several studies directly link this virulence system to unfavourable outcomes in human infections. The culture of P. aeruginosa isolates with functional T3SSs has been linked to increased mortality, persistence, relapse and higher bacterial burdens in acutely colonized or infected patients 137, [151] [152] [153] . Given its important role in pathogenesis, this system is an attractive target for therapeutic intervention. much effort has been directed towards PcrV, which is accessible at the tip of the needle complex 25 and required for translocating effector proteins 23, 24 . Active or passive immunization using PcrV is protective in animal models of infection 19, 154 , seemingly by a direct blockade of the injection of type III proteins into host cells 19 . engineered human anti-PcrV Fab fragments have now been generated and should facilitate the clinical use of this approach 155 . Phase I-II clinical studies are being carried out by Kalobios Pharmaceuticals to evaluate the usefulness of PcrV-specific antibodies in the settings of patients who are mechanically ventilated and individuals with cystic fibrosis.
by residing in cells both before and after secretion, effector proteins remain sheltered from a humoral immune response, and immunization with these proteins is at best minimally effective 19 . For this reason, cell-permeable small-molecule inhibitors have been sought to neutralize exou and exoS. Inhibitors of the PLA 2 activity of exou and the ADPRT activity of exoS have been identified and shown to provide protection in models of infection 156, 157 . Similarly, inhibitors of exsA (the activator necessary to express type III secretion genes) are currently under development 158 . Targeting those patients who are most likely to benefit from such therapies will require the rapid and accurate identification of the effector proteins that are secreted by P. aeruginosa isolates. For this purpose, several assays that can rapidly determine the genetic and phenotypic repertoire of effector proteins of P. aeruginosa clinical isolates have been devised [159] [160] [161] . In a short period of time, therefore, remarkable progress has been made in developing interventions to protect patients from the toxic effects of P. aeruginosa type III secretion.
Concluding remarks
The T3SS is a powerful weapon wielded by P. aeruginosa to enhance the pathogenic process. A complex array of environmental signals are integrated to tightly control the injection of exoS, exoT, exou and exoY into host cells, where they are targeted to specific compartments, are activated by host cell cofactors and manipulate a number of host cell processes. The resulting impairment of the innate immune response and compromise of tissue barriers leads to bacterial dissemination and sepsis.
Despite rapid progress, substantial gaps remain in our understanding of the P. aeruginosa T3SS, and these are the focus of ongoing efforts. Given the extensive variation between P. aeruginosa strains 162 , interrogation of a larger number of isolates may be necessary to uncover any additional effector proteins or at least to exclude their existence. What are the additional regulatory systems that govern type III secretion and how are these systems integrated at the molecular level? What are the cell types that are targeted for type III injection in vivo, what are the consequences of injection to these cells and how are these effects orchestrated to bring about enhanced disease severity? Active investigation of these and many other remaining questions will reveal novel aspects of bacterial pathogenesis in the years to come.
